Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis

Tamara H. Ramwadhdoebe, Lisa G. M. van Baarsen, Maria J. H. Boumans, Stefan T. G. Bruijnen, Mary Safy, Ferco H. Berger, Johanna F. Semmelink, Conny J. van der Laken, Danielle M. Gerlag, Rogier M. Thurlings, Paul P. Tak

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objectives. The exact underlying mechanism of rituximab treatment in patients with RA is poorly defined and knowledge about the effect of B cell depletion on immune cells in secondary lymphoid organs is lacking. We analysed lymphoid tissue responses to rituximab in RA patients. Methods. Fourteen RA patients received 2 1000 mg rituximab intravenously, and lymph node (LN) biopsies were obtained before and 4 weeks after the first infusion. Tissues were examined by flow cytometry, immunohistochemistry and quantitative PCR. LN biopsies from five healthy individuals (HC) served as controls. Results. LN biopsies of RA patients showed increased frequencies of CD21+CD23+IgDhighIgMvariable follicular B cells and CD3+CD25+CD69+ early activated, tissue resident T cells when compared with HCs. After treatment, there was incomplete depletion of LN B cells. There was a significant decrease in CD27IgD+ naïve B cells, and CD27+IgD+ unswitched memory B cells including the CD27+IgD+IgM+ subset and follicular B cells. Strikingly, CD27+IgD switched memory B cells persisted in LN biopsies after rituximab treatment. In the T cell compartment, a significant decrease was observed in the frequency of early activated, tissue resident T cells after rituximab treatment, but late activated T cells persisted. B cell proliferation inducing cytokine IL-21 was higher expressed in LN biopsies of RA patients compared with HC and expression was not affected by rituximab treatment. Conclusion. Rituximab does not cure RA, possibly due to persistence of switched memory B cells in lymphoid tissues suggesting that factors promoting B cell survival and differentiation need to be additionally targeted.
Original languageEnglish
Pages (from-to)1075-1085
JournalRheumatology (United Kingdom)
Volume58
Issue number6
DOIs
Publication statusPublished - 2019

Cite this

Ramwadhdoebe, Tamara H. ; van Baarsen, Lisa G. M. ; Boumans, Maria J. H. ; Bruijnen, Stefan T. G. ; Safy, Mary ; Berger, Ferco H. ; Semmelink, Johanna F. ; van der Laken, Conny J. ; Gerlag, Danielle M. ; Thurlings, Rogier M. ; Tak, Paul P. / Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis. In: Rheumatology (United Kingdom). 2019 ; Vol. 58, No. 6. pp. 1075-1085.
@article{f51353be89854899ac22c3ca2734c1ef,
title = "Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis",
abstract = "Objectives. The exact underlying mechanism of rituximab treatment in patients with RA is poorly defined and knowledge about the effect of B cell depletion on immune cells in secondary lymphoid organs is lacking. We analysed lymphoid tissue responses to rituximab in RA patients. Methods. Fourteen RA patients received 2 1000 mg rituximab intravenously, and lymph node (LN) biopsies were obtained before and 4 weeks after the first infusion. Tissues were examined by flow cytometry, immunohistochemistry and quantitative PCR. LN biopsies from five healthy individuals (HC) served as controls. Results. LN biopsies of RA patients showed increased frequencies of CD21+CD23+IgDhighIgMvariable follicular B cells and CD3+CD25+CD69+ early activated, tissue resident T cells when compared with HCs. After treatment, there was incomplete depletion of LN B cells. There was a significant decrease in CD27IgD+ na{\"i}ve B cells, and CD27+IgD+ unswitched memory B cells including the CD27+IgD+IgM+ subset and follicular B cells. Strikingly, CD27+IgD switched memory B cells persisted in LN biopsies after rituximab treatment. In the T cell compartment, a significant decrease was observed in the frequency of early activated, tissue resident T cells after rituximab treatment, but late activated T cells persisted. B cell proliferation inducing cytokine IL-21 was higher expressed in LN biopsies of RA patients compared with HC and expression was not affected by rituximab treatment. Conclusion. Rituximab does not cure RA, possibly due to persistence of switched memory B cells in lymphoid tissues suggesting that factors promoting B cell survival and differentiation need to be additionally targeted.",
author = "Ramwadhdoebe, {Tamara H.} and {van Baarsen}, {Lisa G. M.} and Boumans, {Maria J. H.} and Bruijnen, {Stefan T. G.} and Mary Safy and Berger, {Ferco H.} and Semmelink, {Johanna F.} and {van der Laken}, {Conny J.} and Gerlag, {Danielle M.} and Thurlings, {Rogier M.} and Tak, {Paul P.}",
year = "2019",
doi = "10.1093/rheumatology/key428",
language = "English",
volume = "58",
pages = "1075--1085",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "6",

}

Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis. / Ramwadhdoebe, Tamara H.; van Baarsen, Lisa G. M.; Boumans, Maria J. H.; Bruijnen, Stefan T. G.; Safy, Mary; Berger, Ferco H.; Semmelink, Johanna F.; van der Laken, Conny J.; Gerlag, Danielle M.; Thurlings, Rogier M.; Tak, Paul P.

In: Rheumatology (United Kingdom), Vol. 58, No. 6, 2019, p. 1075-1085.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis

AU - Ramwadhdoebe, Tamara H.

AU - van Baarsen, Lisa G. M.

AU - Boumans, Maria J. H.

AU - Bruijnen, Stefan T. G.

AU - Safy, Mary

AU - Berger, Ferco H.

AU - Semmelink, Johanna F.

AU - van der Laken, Conny J.

AU - Gerlag, Danielle M.

AU - Thurlings, Rogier M.

AU - Tak, Paul P.

PY - 2019

Y1 - 2019

N2 - Objectives. The exact underlying mechanism of rituximab treatment in patients with RA is poorly defined and knowledge about the effect of B cell depletion on immune cells in secondary lymphoid organs is lacking. We analysed lymphoid tissue responses to rituximab in RA patients. Methods. Fourteen RA patients received 2 1000 mg rituximab intravenously, and lymph node (LN) biopsies were obtained before and 4 weeks after the first infusion. Tissues were examined by flow cytometry, immunohistochemistry and quantitative PCR. LN biopsies from five healthy individuals (HC) served as controls. Results. LN biopsies of RA patients showed increased frequencies of CD21+CD23+IgDhighIgMvariable follicular B cells and CD3+CD25+CD69+ early activated, tissue resident T cells when compared with HCs. After treatment, there was incomplete depletion of LN B cells. There was a significant decrease in CD27IgD+ naïve B cells, and CD27+IgD+ unswitched memory B cells including the CD27+IgD+IgM+ subset and follicular B cells. Strikingly, CD27+IgD switched memory B cells persisted in LN biopsies after rituximab treatment. In the T cell compartment, a significant decrease was observed in the frequency of early activated, tissue resident T cells after rituximab treatment, but late activated T cells persisted. B cell proliferation inducing cytokine IL-21 was higher expressed in LN biopsies of RA patients compared with HC and expression was not affected by rituximab treatment. Conclusion. Rituximab does not cure RA, possibly due to persistence of switched memory B cells in lymphoid tissues suggesting that factors promoting B cell survival and differentiation need to be additionally targeted.

AB - Objectives. The exact underlying mechanism of rituximab treatment in patients with RA is poorly defined and knowledge about the effect of B cell depletion on immune cells in secondary lymphoid organs is lacking. We analysed lymphoid tissue responses to rituximab in RA patients. Methods. Fourteen RA patients received 2 1000 mg rituximab intravenously, and lymph node (LN) biopsies were obtained before and 4 weeks after the first infusion. Tissues were examined by flow cytometry, immunohistochemistry and quantitative PCR. LN biopsies from five healthy individuals (HC) served as controls. Results. LN biopsies of RA patients showed increased frequencies of CD21+CD23+IgDhighIgMvariable follicular B cells and CD3+CD25+CD69+ early activated, tissue resident T cells when compared with HCs. After treatment, there was incomplete depletion of LN B cells. There was a significant decrease in CD27IgD+ naïve B cells, and CD27+IgD+ unswitched memory B cells including the CD27+IgD+IgM+ subset and follicular B cells. Strikingly, CD27+IgD switched memory B cells persisted in LN biopsies after rituximab treatment. In the T cell compartment, a significant decrease was observed in the frequency of early activated, tissue resident T cells after rituximab treatment, but late activated T cells persisted. B cell proliferation inducing cytokine IL-21 was higher expressed in LN biopsies of RA patients compared with HC and expression was not affected by rituximab treatment. Conclusion. Rituximab does not cure RA, possibly due to persistence of switched memory B cells in lymphoid tissues suggesting that factors promoting B cell survival and differentiation need to be additionally targeted.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85065039132&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30649469

U2 - 10.1093/rheumatology/key428

DO - 10.1093/rheumatology/key428

M3 - Article

VL - 58

SP - 1075

EP - 1085

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 6

ER -